BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26507258)

  • 1. PDGFRB mutation causes autosomal-dominant Penttinen syndrome.
    Aminkeng F
    Clin Genet; 2015 Dec; 88(6):531. PubMed ID: 26507258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Point Mutation in PDGFRB Causes Autosomal-Dominant Penttinen Syndrome.
    Johnston JJ; Sanchez-Contreras MY; Keppler-Noreuil KM; Sapp J; Crenshaw M; Finch NA; Cormier-Daire V; Rademakers R; Sybert VP; Biesecker LG
    Am J Hum Genet; 2015 Sep; 97(3):465-74. PubMed ID: 26279204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Premature Aging Syndrome, Penttinen Type: Report of a Chinese Case with a PDGFRB Mutation.
    Zhang Z; Zheng S; Zheng S; Wang Y; Xu XG; Gao XH; Chen HD
    Acta Derm Venereol; 2018 Oct; 98(9):912-913. PubMed ID: 29944170
    [No Abstract]   [Full Text] [Related]  

  • 4. Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions.
    Bredrup C; Cristea I; Safieh LA; Di Maria E; Gjertsen BT; Tveit KS; Thu F; Bull N; Edward DP; Hennekam RCM; Høvding G; Haugen OH; Houge G; Rødahl E; Bruland O
    Hum Mol Genet; 2021 Mar; 30(1):72-77. PubMed ID: 33450762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome.
    Bredrup C; Stokowy T; McGaughran J; Lee S; Sapkota D; Cristea I; Xu L; Tveit KS; Høvding G; Steen VM; Rødahl E; Bruland O; Houge G
    Eur J Hum Genet; 2019 Apr; 27(4):574-581. PubMed ID: 30573803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion of the phenotype of Kosaki overgrowth syndrome.
    Minatogawa M; Takenouchi T; Tsuyusaki Y; Iwasaki F; Uehara T; Kurosawa K; Kosaki K; Curry CJ
    Am J Med Genet A; 2017 Sep; 173(9):2422-2427. PubMed ID: 28639748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First case report of Penttinen syndrome from India.
    Aggarwal B; Correa ARE; Gupta N; Jana M; Kabra M
    Am J Med Genet A; 2022 Feb; 188(2):683-687. PubMed ID: 34799960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penttinen syndrome-associated PDGFRB Val665Ala variant causes aberrant constitutive STAT1 signalling.
    Nédélec A; Guérit EM; Dachy G; Lenglez S; Wong LS; Arts FA; Demoulin JB
    J Cell Mol Med; 2022 Jul; 26(14):3902-3912. PubMed ID: 35689379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Master of Puppets: Pleiotropy of PDGFRB and its Relationship to Multiple Diseases.
    Moura DAP; de Oliveira JRM
    J Mol Neurosci; 2020 Dec; 70(12):2102-2106. PubMed ID: 32613555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome.
    Iznardo H; Bredrup C; Bernal S; Gladkauskas T; Mascaró JM; Roé E; Baselga E
    Am J Med Genet A; 2022 Apr; 188(4):1233-1238. PubMed ID: 34894066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acro-osteolysis, keloid like-lesions, distinctive facial features, and overgrowth: two newly recognized patients with premature aging syndrome, Penttinen type.
    Zufferey F; Hadj-Rabia S; De Sandre-Giovannoli A; Dufier JL; Leheup B; Schweitze C; Bodemer C; Cormier-Daire V; Le Merrer M
    Am J Med Genet A; 2013 Jul; 161A(7):1786-91. PubMed ID: 23720404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrastructural skin changes in Egyptian mandibuloacral dysplasia patients with p.Arg527Leu LMNA mutation and in their asymptomatic heterozygotic mothers.
    Al-Haggar M; Shams A; Madej-Pilarczyk A; Barakat T; Puzianowska-Kuznicka M
    J Clin Pathol; 2013 Nov; 66(11):1000-4. PubMed ID: 23775434
    [No Abstract]   [Full Text] [Related]  

  • 13. STAT1 modulates tissue wasting or overgrowth downstream from PDGFRβ.
    He C; Medley SC; Kim J; Sun C; Kwon HR; Sakashita H; Pincu Y; Yao L; Eppard D; Dai B; Berry WL; Griffin TM; Olson LE
    Genes Dev; 2017 Aug; 31(16):1666-1678. PubMed ID: 28924035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel de novo PDGFRB variant in a child with severe cerebral malformations, intracerebral calcifications, and infantile myofibromatosis.
    Guimier A; Gordon CT; Hully M; Blauwblomme T; Minard-Colin V; Bole-Feysot C; Nitschké P; Oufadem M; Boddaert N; Sarnacki S; Amiel J
    Am J Med Genet A; 2019 Jul; 179(7):1304-1309. PubMed ID: 31004414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal stem cell fate defects caused by Pdgfrb activating mutation.
    Kwon HR; Kim JH; Woods JP; Olson LE
    Development; 2021 Dec; 148(23):. PubMed ID: 34738614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DLL4 loss-of-function heterozygous mutations cause Adams-Oliver syndrome.
    Aminkeng F
    Clin Genet; 2015 Dec; 88(6):532. PubMed ID: 26419402
    [No Abstract]   [Full Text] [Related]  

  • 17. Hemifacial microsomia, external auditory canal atresia, deafness and Mullerian anomalies associated with acro-osteolysis: a new autosomal recessive syndrome?
    Brady AF; Winter RM; Wilson LC; Tatnall FM; Sheridan RJ; Garrett C
    Clin Dysmorphol; 2002 Jul; 11(3):155-61. PubMed ID: 12072792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kosaki overgrowth syndrome: A newly identified entity caused by pathogenic variants in platelet-derived growth factor receptor-beta.
    Takenouchi T; Okuno H; Kosaki K
    Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):650-657. PubMed ID: 31710779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in PDGFRB and NOTCH3 are the first genetic causes identified for autosomal dominant infantile myofibromatosis.
    Lee JW
    Clin Genet; 2013 Oct; 84(4):340-1. PubMed ID: 23865785
    [No Abstract]   [Full Text] [Related]  

  • 20. A new acro-osteolysis syndrome caused by duplications including PTHLH.
    Gray MJ; van Kogelenberg M; Beddow R; Morgan T; Wordsworth P; Shears DJ; Robertson SP; Hurst JA
    J Hum Genet; 2014 Sep; 59(9):484-7. PubMed ID: 25007883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.